Insilico signs US$888 million AI drug-development deal days after Hong Kong IPO
The deal comes just days after the US company’s shares debuted following its initial public offering (IPO), which raised HK$2.28 billion (US$293 million) after the public portion was oversubscribed 1,427 times. The multi-year partnership with Servier, unveiled on Saturday, would make Insilico eligible for up to US$32 million in upfront and near-term research and development…